{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:25:30Z","timestamp":1792088730190,"version":"4.4.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.atherosclerosis.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T02:02:06Z","timestamp":1496455326000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"special_numbering":"C","title":["Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention"],"prefix":"10.1016","volume":"263","author":[{"given":"Farzad","family":"Masoudkabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Gotay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ignaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib1","series-title":"Global Status Report on Noncommunicable Diseases 2014","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib2","first-page":"278","article-title":"Patient-reported outcomes in cancer: a review of recent research and policy initiatives","volume":"57","author":"Lipscomb","year":"2007","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1474515111430928","article-title":"Depression and health-related quality of life in people with coronary heart disease: a systematic review","volume":"11","author":"Dickens","year":"2012","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/450494a","article-title":"Grand challenges in chronic non-communicable diseases","volume":"450","author":"Daar","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib5","series-title":"The World Health Report 2002-Reducing Risks, Promoting Healthy Life","year":"2002"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib6","series-title":"Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2006.06.082","article-title":"Activation of the canonical Wnt\/beta-catenin pathway enhances monocyte adhesion to endothelial cells","volume":"347","author":"Lee","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib9","first-page":"221","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control CCC"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib10","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1196\/annals.1414.011","article-title":"Captopril as a potential inhibitor of lung tumor growth and metastasis","volume":"1138","author":"Attoub","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ehj.2003.12.007","article-title":"The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm","volume":"25","author":"Olijhoek","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1517\/14728222.2014.938051","article-title":"NF-kappaB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links","volume":"18","author":"Pateras","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib14","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.atherosclerosis.2007.05.026","article-title":"HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages","volume":"195","author":"Vink","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib15","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1161\/CIRCULATIONAHA.107.696922","article-title":"Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development","volume":"115","author":"Agrawal","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.freeradbiomed.2012.02.035","article-title":"Emerging avenues linking inflammation and cancer","volume":"52","author":"Kundu","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib18","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"Int. J. Cancer. J. Int. du Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2013.08.014","article-title":"Molecular mechanisms underlying chronic inflammation-associated cancers","volume":"345","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","article-title":"Inflammation, a key event in cancer development","volume":"4","author":"Lu","year":"2006","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib22","doi-asserted-by":"crossref","first-page":"31629","DOI":"10.1074\/jbc.M212831200","article-title":"Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells","volume":"278","author":"Morrow","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2174\/156652410793384187","article-title":"Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease","volume":"10","author":"Cabarcas","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pharmthera.2010.11.002","article-title":"AMPK and vasculoprotection","volume":"131","author":"Ewart","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.08.012","article-title":"AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A\/NF-kappaB\/LOX-1 pathway","volume":"85","author":"Chen","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1113\/jphysiol.2006.108324","article-title":"AMPK and cell proliferation\u2013AMPK as a therapeutic target for atherosclerosis and cancer","volume":"574","author":"Motoshima","year":"2006","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1523\/JNEUROSCI.4288-03.2004","article-title":"5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase","volume":"24","author":"Giri","year":"2004","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib29","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/0008-5472.CAN-04-3025","article-title":"Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype","volume":"65","author":"Swinnen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/carcin\/bgg032","article-title":"AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression","volume":"24","author":"Li","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0014-5793(02)03110-1","article-title":"Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells","volume":"526","author":"Meisse","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.bcp.2004.01.020","article-title":"Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase","volume":"67","author":"Saitoh","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2004.06.133","article-title":"AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms","volume":"321","author":"Xiang","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1748-1716.2009.01980.x","article-title":"AMP-activated protein kinase and cancer","volume":"196","author":"Wang","year":"2009","journal-title":"Acta Physiol. (Oxf. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib35","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1038\/emm.2016.16","article-title":"AMPK activators: mechanisms of action and physiological activities","volume":"48","author":"Kim","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib36","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev. Res. (Phila. Pa.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2012.12.008","article-title":"LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin","volume":"23","author":"Shackelford","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.ATV.21.3.372","article-title":"Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL","volume":"21","author":"Chen","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib41","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2353\/ajpath.2009.080611","article-title":"Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone","volume":"174","author":"Nakaya","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib42","first-page":"528","article-title":"Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update","volume":"75","author":"Wang","year":"2011","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jjcc.2015.05.004","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery","volume":"66","author":"Ivanova","year":"2015","journal-title":"J.\u00a0Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib44","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1210\/endo.142.7.8272","article-title":"Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells","volume":"142","author":"Sugawara","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib45","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.3748\/wjg.v20.i23.7137","article-title":"Emerging role of the beta-catenin-PPARgamma axis in the pathogenesis of colorectal cancer","volume":"20","author":"Sabatino","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib46","doi-asserted-by":"crossref","first-page":"968040","DOI":"10.1155\/2012\/968040","article-title":"Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer","volume":"2012","author":"Sikka","year":"2012","journal-title":"PPAR Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/cgt.2014.16","article-title":"The PPARgamma agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells","volume":"21","author":"Yan","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib48","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1210\/me.2007-0421","article-title":"Minireview: nuclear receptors and breast cancer","volume":"22","author":"Conzen","year":"2008","journal-title":"Mol. Endocrinol. (Baltim. Md.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12013-011-9253-x","article-title":"Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-gamma ligands via Wnt signaling pathway","volume":"62","author":"Liu","year":"2012","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2015.10.057","article-title":"Effects of Thiazolidinediones on metabolism and cancer: relative influence of PPARgamma and IGF-1 signaling","volume":"768","author":"Mughal","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ppul.20338","article-title":"Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?","volume":"41","author":"Denning","year":"2006","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00592-013-0504-8","article-title":"Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials","volume":"51","author":"Monami","year":"2014","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.atherosclerosis.2008.05.029","article-title":"Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials","volume":"202","author":"Geng","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib56","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.14310\/horm.2002.1671","article-title":"Cardiovascular safety of type 2 diabetes medications: review of existing literature and clinical implications","volume":"15","author":"Paredes","year":"2016","journal-title":"Horm. (Athens, Greece)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib60","doi-asserted-by":"crossref","first-page":"23398","DOI":"10.1074\/jbc.M110.100321","article-title":"Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis","volume":"285","author":"Schneider","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib61","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3892\/ijmm.2014.1942","article-title":"Palmitic acid exerts pro-inflammatory effects on vascular smooth muscle cells by inducing the expression of C-reactive protein, inducible nitric oxide synthase and tumor necrosis factor-alpha","volume":"34","author":"Wu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib62","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.bmcl.2015.08.087","article-title":"Progress in the development of fatty acid synthase inhibitors as anticancer targets","volume":"25","author":"Mullen","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib63","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/labinvest.2008.97","article-title":"Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer","volume":"88","author":"Fiorentino","year":"2008","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib64","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/sj.onc.1208555","article-title":"FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis","volume":"24","author":"Bandyopadhyay","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib65","first-page":"2745","article-title":"Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells","volume":"56","author":"Pizer","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib66","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bbrc.2015.05.108","article-title":"Up-regulation of fatty acid synthase induced by EGFR\/ERK activation promotes tumor growth in pancreatic cancer","volume":"463","author":"Bian","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib67","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2174\/138945011797635803","article-title":"Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease","volume":"12","author":"Ploplis","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2012.09074.x","article-title":"PAI-1, progress in understanding the clinical problem and its aetiology","volume":"157","author":"Iwaki","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib69","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/ATVBAHA.111.241927","article-title":"Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer","volume":"32","author":"Hursting","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib70","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/jnci\/djs377","article-title":"Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function","volume":"104","author":"Fang","year":"2012","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib71","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib72","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/joim.12012","article-title":"Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery","volume":"273","author":"Sjostrom","year":"2013","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1684\/ecn.2011.0295","article-title":"Short-term effect of weight loss through restrictive bariatric surgery on serum levels of vaspin in morbidly obese subjects","volume":"22","author":"Golpaie","year":"2011","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12020-012-9821-x","article-title":"Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery","volume":"44","author":"Karbaschian","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib76","first-page":"566","article-title":"Decreased plasma levels of ceruloplasmin after diet-induced weight loss in obese women","volume":"35","author":"Tajik","year":"2012","journal-title":"J.\u00a0Endocrinol. Investig."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib77","first-page":"211","article-title":"Effect of diet-induced weight loss on inflammatory cytokines in obese women","volume":"36","author":"Tajik","year":"2013","journal-title":"J.\u00a0Endocrinol. Investig."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib78","first-page":"263","article-title":"The multifactorial role of leptin in driving the breast cancer microenvironment, Nature reviews","volume":"8","author":"Ando","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib79","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jcp.20472","article-title":"Leptin and cancer","volume":"207","author":"Garofalo","year":"2006","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib80","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2012.12.029","article-title":"Adipokines as mediators of endothelial function and atherosclerosis","volume":"227","author":"Ntaios","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib81","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1073\/pnas.93.12.5793","article-title":"Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes","volume":"93","author":"Kallen","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib82","doi-asserted-by":"crossref","first-page":"431763","DOI":"10.1155\/2008\/431763","article-title":"Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer","volume":"2008","author":"Giaginis","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib84","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1530\/JME-13-0152","article-title":"A\u00a0new link between diabetes and cancer: enhanced WNT\/beta-catenin signaling by high glucose","volume":"52","author":"Garcia-Jimenez","year":"2014","journal-title":"J.\u00a0Mol. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib85","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.celrep.2015.09.028","article-title":"Impaired LRP6-TCF7L2 activity enhances smooth muscle cell plasticity and causes coronary artery disease","volume":"13","author":"Srivastava","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib86","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.1019443108","article-title":"Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation","volume":"108","author":"Keramati","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib87","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1136370","article-title":"LRP6 mutation in a family with early coronary disease and metabolic risk factors","volume":"315","author":"Mani","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib88","doi-asserted-by":"crossref","first-page":"H2864","DOI":"10.1152\/ajpheart.00982.2007","article-title":"Wnt5a is expressed in murine and human atherosclerotic lesions","volume":"294","author":"Christman","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib89","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.1000181","article-title":"Wnt5a induces endothelial inflammation via beta-catenin-independent signaling","volume":"185","author":"Kim","year":"2010","journal-title":"J.\u00a0Immunol. (Baltim. Md. 1950)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib90","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1172\/JCI24140","article-title":"Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals","volume":"115","author":"Shao","year":"2005","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib91","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tem.2012.06.001","article-title":"Wnt signaling in cardiovascular physiology","volume":"23","author":"Marinou","year":"2012","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib92","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cell.2013.06.030","article-title":"Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling","volume":"154","author":"Hirabayashi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib93","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/CIRCRESAHA.108.183863","article-title":"Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance","volume":"103","author":"Liu","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib94","first-page":"19","article-title":"Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis","volume":"85","author":"Go","year":"2012","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib95","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1074\/jbc.M111.286724","article-title":"Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure","volume":"287","author":"Liu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib96","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1074\/jbc.M111.295287","article-title":"LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake","volume":"287","author":"Ye","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmet.2013.01.009","article-title":"LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans","volume":"17","author":"Singh","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib98","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/humu.22360","article-title":"Rare nonconservative LRP6 mutations are associated with metabolic syndrome","volume":"34","author":"Singh","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cmet.2013.11.023","article-title":"The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue","volume":"19","author":"Go","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib100","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.18632\/oncotarget.2769","article-title":"Wnt signaling, de novo lipogenesis, adipogenesis and ectopic fat","volume":"5","author":"Song","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib101","first-page":"3436","article-title":"Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a","volume":"29","author":"Wang","year":"2015","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib102","doi-asserted-by":"crossref","first-page":"9129","DOI":"10.1038\/sj.onc.1208123","article-title":"LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution","volume":"23","author":"Li","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib103","doi-asserted-by":"crossref","first-page":"e36565","DOI":"10.1371\/journal.pone.0036565","article-title":"Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion","volume":"7","author":"Tung","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib104","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1073\/pnas.0911220107","article-title":"LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/onc.2009.339","article-title":"Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis","volume":"29","author":"Zhang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib106","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/onc.2014.416","article-title":"Oncogenic KRAS signalling promotes the Wnt\/beta-catenin pathway through LRP6 in colorectal cancer","volume":"34","author":"Lemieux","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib107","doi-asserted-by":"crossref","first-page":"e17978","DOI":"10.1371\/journal.pone.0017978","article-title":"Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis","volume":"6","author":"Muendlein","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib108","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2350-14-8","article-title":"Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population","volume":"14","author":"Wang","year":"2013","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2350-10-15","article-title":"Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis","volume":"10","author":"Tong","year":"2009","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00109-007-0203-4","article-title":"TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis","volume":"85","author":"Cauchi","year":"2007","journal-title":"J.\u00a0Mol. Med. (Berl. Ger.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib111","first-page":"9355","article-title":"Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib112","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2337\/dc07-2131","article-title":"Variation in TCF7L2 and increased risk of colon cancer: the Aherosclerosis Risk in Communities (ARIC) Study","volume":"31","author":"Folsom","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib113","first-page":"152","article-title":"Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population","volume":"29","author":"Domenyuk","year":"2007","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib114","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-012-2299-7","article-title":"Associations between TCF7L2 polymorphisms and risk of breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study","volume":"136","author":"Connor","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7150\/ijms.10953","article-title":"Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer","volume":"12","author":"Chen","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib116","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1471-2407-6-268","article-title":"Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study","volume":"6","author":"Burwinkel","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib117","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0896-6273(95)90286-4","article-title":"minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila","volume":"14","author":"Tejedor","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib118","doi-asserted-by":"crossref","first-page":"39819","DOI":"10.1074\/jbc.M104091200","article-title":"Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells","volume":"276","author":"Yang","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib119","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18632\/genesandcancer.29","article-title":"Mirk kinase inhibition blocks the in\u00a0vivo growth of pancreatic cancer cells","volume":"5","author":"Deng","year":"2014","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib120","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.3390\/ijms14035560","article-title":"Mirk\/dyrk1B kinase in ovarian cancer","volume":"14","author":"Friedman","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib121","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.4161\/cbt.8.17.9322","article-title":"Mirk\/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells","volume":"8","author":"Gao","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib122","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1301824","article-title":"A\u00a0form of the metabolic syndrome associated with mutations in DYRK1B","volume":"370","author":"Keramati","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib123","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.metabol.2011.10.013","article-title":"Methylenetetrahydrofolate reductase C677T gene polymorphism and coronary artery disease in a Chinese Han population: a meta-analysis","volume":"61","author":"Li","year":"2012","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gene.2015.03.062","article-title":"Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility: a meta-analysis","volume":"565","author":"Hou","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.arcmed.2011.11.009","article-title":"Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls","volume":"42","author":"Xuan","year":"2011","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib126","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/euhj.1999.1914","article-title":"Homocysteine and atherothrombosis\u2013mechanisms for injury","volume":"21","author":"Thambyrajah","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmg.2014.10.004","article-title":"Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases","volume":"58","author":"Liew","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvs.2008.10.004","article-title":"Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis","volume":"49","author":"Khandanpour","year":"2009","journal-title":"J.\u00a0Vasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1179\/1743132815Y.0000000008","article-title":"Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene (MTHFR gene) with ischemic stroke: a meta-analysis","volume":"37","author":"Kumar","year":"2015","journal-title":"Neurol. Res."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00207454.2014.984295","article-title":"Association between the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and ischemic stroke in the Chinese population: a meta-analysis","volume":"125","author":"Zhu","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib131","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2012.07.038","article-title":"Association of MTHFR 677T variant allele with risk of intracerebral haemorrhage: a meta-analysis","volume":"323","author":"Gao","year":"2012","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib132","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/gtmb.2012.0295","article-title":"Association of the C677T polymorphism in the MTHFR gene with hemorrhagic stroke: a meta-analysis","volume":"17","author":"Kang","year":"2013","journal-title":"Genet. Test. Mol. Biomarker."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib133","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0083-6729(08)00413-5","article-title":"Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease","volume":"79","author":"Thomas","year":"2008","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib134","first-page":"389","article-title":"Statins, ACE inhibitors and ARBs in cardiovascular disease, Best practice & research","volume":"23","author":"Montecucco","year":"2009","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-014-2236-4","article-title":"HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?","volume":"94","author":"Bockorny","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib137","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annepidem.2011.10.006","article-title":"Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk","volume":"22","author":"Simon","year":"2012","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib138","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib139","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib140","first-page":"795","article-title":"Statins: perspectives in cancer therapeutics","volume":"45","author":"Corcos","year":"2013","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib141","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.yjmcc.2015.07.005","article-title":"The role of DNA damage and repair in atherosclerosis: a review","volume":"86","author":"Shah","year":"2015","journal-title":"J.\u00a0Mol. Cell. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4239\/wjd.v6.i2.352","article-title":"Statin use and risk of diabetes mellitus","volume":"6","author":"Chogtu","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib143","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib144","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","article-title":"Are statins diabetogenic?","volume":"26","author":"Sampson","year":"2011","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib146","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jamcollsurg.2007.01.067","article-title":"Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma","volume":"204","author":"Arafat","year":"2007","journal-title":"J.\u00a0Am. Coll. Surg."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib147","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3181\/00379727-210-43942","article-title":"Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells","volume":"210","author":"Reddy","year":"1995","journal-title":"Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. (New York N.Y.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib148","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<761::AID-IJC16>3.0.CO;2-1","article-title":"Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","volume":"81","author":"Prontera","year":"1999","journal-title":"Int. J. Cancer J. Int. du Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib149","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","article-title":"Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer","volume":"2","author":"Escobar","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.mnh.0000196146.65330.ea","article-title":"The tissue renin-angiotensin system and intracellular signalling","volume":"15","author":"Fleming","year":"2006","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14712598.6.3.243","article-title":"Manipulating the angiotensin system\u2013new approaches to the treatment of solid tumours","volume":"6","author":"Ino","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib152","first-page":"543","article-title":"Renin in blood vessels in human pulmonary tumors. An immunohistochemical and biochemical study","volume":"130","author":"Taylor","year":"1988","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib153","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000069792","article-title":"Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor","volume":"23","author":"Yoshiji","year":"2002","journal-title":"Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib154","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJMp1213380","article-title":"Aspirin in the secondary prevention of cardiovascular disease","volume":"368","author":"Parekh","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib156","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib157","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(11)61654-1","article-title":"Are we ready to recommend aspirin for cancer prevention?","volume":"379","author":"Chan","year":"2012","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib158","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib159","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.atherosclerosis.2017.06.001_bib160","first-page":"664","article-title":"Exploring unknowns in cardiology, Nature reviews","volume":"11","author":"Alfieri","year":"2014","journal-title":"Cardiology"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017302484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017302484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:37:05Z","timestamp":1758155825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017302484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":160,"alternative-id":["S0021915017302484"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.06.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}